Release date: 2024-08-27 14:10:15 Article From: Lucius Laos Recommended: 148
Balversa is an oral anticancer drug that specializes in FGFR mutant tumors, such as urothelial carcinoma, and effectively inhibits tumor proliferation, but has not yet been introduced in the domestic market.
The therapeutic effect of Balversa is relatively good, which is mainly reflected in the following two points:
As a targeted drug, Balversa has shown significant therapeutic effects in cancer patients with FGFR gene mutations. It can effectively inhibit the growth and spread of tumor cells, help patients control the disease, and prolong survival.
Data from multiple clinical trials have shown that Balversa can significantly improve overall survival and progression-free survival while improving patients' quality of life in the treatment of cancers such as locally advanced or metastatic urothelial carcinoma.
After discussing the therapeutic effect of Balversa, we have to face up to the differences in its therapeutic effect among different individuals. Understanding these differences allows us to more fully assess the therapeutic value of Balversa.
There are individual differences in the therapeutic effect of Balversa, which are mainly reflected in:
The degree of response to Balversa is affected by the type and status of the FGFR gene mutation in the patient's body. Patients with different genotypes may have different susceptibility and resistance to drugs, which can affect the effectiveness of treatment.
Clinical conditions such as the patient's age, gender, performance status, and underlying medical conditions will also affect the therapeutic efficacy of Balversa. Younger, well-performing patients may be more tolerant of treatment and have better outcomes.
In view of the individual differences in the therapeutic effect of Balversa, elderly patients should pay special attention to their physical response and drug metabolism characteristics when using Balversa to ensure that it is safe and effective.
When using Balversa in the elderly, special attention should be paid to the following two points:
Kidney function may be reduced in older people, and Balversa is partially dependent on the kidneys for metabolism and excretion. During the use of Balversa, renal function should be monitored regularly to ensure the normal metabolism and excretion of the drug in the body and reduce the occurrence of adverse reactions.
Older people may have a weaker ability to metabolize and excrete drugs and may have a variety of chronic diseases, so doctors should carefully adjust the dosage according to the specific situation of the patient to ensure that the therapeutic effect is achieved and the risk of overtreatment is avoided.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: